LEQEMBI IQLIK

LaunchmAb

lecanemab-irmb

Eisai
BLASUBCUTANEOUSINJECTABLE
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100

Mechanism of Action

Amyloid Beta-directed Antibody Interactions

Pharmacologic Class:

Amyloid Beta-directed Antibody

Company
E
Eisai
China - Liaoning
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers